Dluh/Vlastní kapitál společnosti Theratechnologies

Jaká je hodnota metriky Dluh/Vlastní kapitál společnosti Theratechnologies?

Hodnota metriky Dluh/Vlastní kapitál společnosti Theratechnologies Inc. je N/A

Jaká je definice metriky Dluh/Vlastní kapitál?



Poměr dluhu k vlastnímu kapitálu (debt to equity ratio) udává podíl vlastního kapitálu a cizích zdrojů na financování majetku společnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Čemu se věnuje společnost Theratechnologies?

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.